When Your Name on the Label Becomes a License Requirement

In today’s pharmaceutical industry, companies can face state licensing requirements in jurisdictions where they do not manufacture, ship, sell, distribute, or maintain a physical presence.

In some cases, the deciding factor is not what a company does in a state, but whether their name is on the label of a product consumed by a patient there. We call these “Labeler States” or “Ends-Up-In States.”

For manufacturers, virtual manufacturers, relabelers, and repackagers, that reality can come as a surprise.

Why States Care About the Label

For many regulators, the label represents accountability, and that is where assumptions can break down for companies.

The label identifies the party associated with a product and often becomes a focal point when questions arise involving recalls, product quality, traceability, or supply chain oversight.

That’s why there are now 17 states that are requiring companies to obtain licensure if their name appears on a label, including: Alabama, Arizona, Texas, South Carolina, and Vermont among others.

There are also at least five additional states which LighthouseAI recommends obtaining licensure as the state does not provide clear or definitive guidance regarding requirements for label holders whose products are ultimately sold or shipped into the jurisdiction.

The Guidance Problem: Clear Answers in Some States, Gray Areas in Others

State Boards of Pharmacy do not apply a uniform approach to this issue.

State boards such as Connecticut, Texas, and Arizona provide relatively clear guidance on when a label holder must be licensed. Others decline to offer interpretive guidance and instead refer companies back to statutes, rules, and regulations.

As a result, companies are often left operating in gray areas where licensing obligations are not always clearly defined.

How DSCSA Increased the Focus on Supply Chain Accountability

The Drug Supply Chain Security Act (DSCSA) did not create label holder licensing obligations, but it reinforced the industry’s focus on traceability and accountability throughout the pharmaceutical supply chain.

As supply chain transparency has increased, regulators have become more attentive to the parties associated with a product, including companies that may never physically handle products, but still appear on labeling, documentation, or supply chain records.

Why This Matters in Practice

For companies, this is not simply a technical compliance issue. It can affect planning, timelines, budgets, and product launches.

Label holder obligations can surface unexpectedly, particularly in virtual manufacturers. Some companies discover late in the initial commercialization process that they may have licensing exposure in states where they assumed none existed. Others spend significant time interpreting rules that do not provide definitive answers.

That is why this area often requires early analysis and proactive planning.

In today’s regulatory environment, a company’s compliance footprint is no longer defined solely by where it manufactures, ships, or sells. Increasingly, accountability follows the role a company plays in the supply chain, and for virtual manufacturers, a name on the label can become a trigger that some organizations don’t expect.

Are your products ending up in states where you aren’t currently licensed?

LighthouseAI specializes in helping pharmaceutical supply chain companies navigate the complexity of state licensing requirements. Contact us today, and we’ll determine your licensing requirements and help close any compliance gaps for labeler states, otherwise known as Ends-Up-In states.